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2418Peripheral artery disease com-
monly affects the superﬁcial
femoral artery (SFA). To treat the
broad range of symptoms, current
interventional options include
bypass surgery and endovascular
therapies, such as percutaneous
transluminal angioplasty (PTA)
and self-expanding metallic stent
implantation. Traditional bypass
surgery provides durable outcomes
but is associated with increased
morbidity and prolonged recovery
relative to the less invasive endo-
vascular approaches (1). Longer-term studies of endovascular interventions also highlight
limited outcomes, particularly for more challenging lesions such
as chronic occlusions and long-segment SFA disease. As
previously reported, the 1-year patency rate following PTA of
the SFA is between 22% and 60% (2–4). Although stents
improve initial patency compared with PTA alone, the sus-
tained beneﬁt remains suboptimal, in particular for longer SFA
lesions, with 1-year patency rates of 63% to 81% (4–6).
In an effort to combat the formidable challenge of neo-
intimal hyperplasia that confronts all endovascular inter-
ventions in the femoropopliteal segments, interventional
treatments that include local drug delivery to the SFA have
been investigated with the intent to limit restenosis in
much the same way as drug-eluting stents (DES) have
shown improved outcomes in the coronary arteries (7–9).
These SFA treatments have included paclitaxel-coated
balloons, which have shown promise compared with PTA
alone (10,11). Nitinol stents modiﬁed to deliver anti-
proliferative agents to the vessel wall have also been eval-
uated, but sustained beneﬁt has not previously been
demonstrated (7–9).
The purpose of the Zilver PTX Randomized Clinical
Trial and Single-Arm Study was to investigate the safety and
effectiveness of a paclitaxel-coated DES for treating femo-
ropopliteal disease. The DES evaluated in these studies is
the Zilver PTX nitinol stent (Cook Medical, Bloomington,
Indiana), which incorporates a self-expanding, ﬂexible
nitinol stent platform with a 3 mg/mm2 polymer-free coating
of paclitaxel on its outer surface. As reported previously,
these studies support the 1-year safety and effectiveness of
the DES in patients with de novo or restenotic lesions of the
above-the-knee femoropopliteal artery (12,13). Moreover, in
the randomized trial, implantation of the DES provided
superior 1-year patency compared with both PTA and
provisional bare-metal stent (BMS) placement (12). Herein,
2-year outcomes from both studies are reported.
Methods
Detailed descriptions of study design, inclusion and
exclusion criteria, methods, and follow-up through 1 year forthe Zilver PTX Randomized Clinical Trial and Single-Arm
Study were previously reported (12,13). The inclusion
criteria for the randomized trial included Rutherford
category 2, 50% diameter stenosis, reference vessel
diameter 4 to 9 mm, lesion length up to 14 cm, and at least
1 patent runoff vessel with <50% stenosis throughout its
course. Exclusion criteria included untreated >50% stenosis
of the inﬂow tract and previous target vessel stent placement.
The inclusion and exclusion criteria for the complementary
single-arm study were broader, and the study included
previous target vessel stent placement and lesions up to
28 cm. Approval was obtained from each site’s institutional
review board or ethics committee, and patients provided
written informed consent. Both studies were overseen by an
independent data safety monitoring board and monitored
in accordance with International Conference on Harmo-
nisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use Good Clinical Practices.
To determine their relationship to the study procedure or
device, major adverse events were adjudicated by an inde-
pendent clinical events committee. Brieﬂy, the studies
enrolled a total of 1,261 patients with symptomatic disease
of the above-the-knee femoropopliteal arteries. The
randomized trial included 238 patients randomized to PTA
and 236 patients randomized to primary DES treatment
(Fig. 1). One hundred twenty patients with acute PTA
failure were subsequently randomized to provisional DES
(n ¼ 61) or provisional BMS (n ¼ 59; Zilver, Cook
Medical) placement. The single-arm study enrolled
787 patients treated with the DES. In total, 1,084 patients
received the DES (Zilver PTX).
Interventions. Rutherford classiﬁcation, ankle-brachial
index (ABI), and Walking Impairment Questionnaire
(WIQ; a validated measure of patient-perceived walking
performance) (14) were assessed before the procedure. Stents
were placed at least 1 cm below the SFA origin and above
the medial femoral epicondyle to fully cover the target
lesion(s). Pre-dilation and post-dilation were at the physi-
cian’s discretion, with residual stenosis <30% required for
procedural success. For patients randomized to the PTA
group, PTA was performed according to institutional
standard practice, and patients with acute PTA failure
(i.e., 30% stenosis or a 5 mm Hg mean trans-stenotic
pressure gradient) underwent secondary randomization to
provisional BMS or provisional DES placement.
Medical therapy. The same antiplatelet regimen was rec-
ommended for all patients: clopidogrel (ticlopidine in Japan)
starting at least 24 h before the intervention or a procedural
loading dose of 300 mg, continued clopidogrel or ticlopidine
therapy for at least 60 days post-procedurally, and lifelong
aspirin therapy.
Follow-up. At 18 months, patients were contacted by
telephone for an assessment of overall medical condition. At
2 years, patients underwent a clinical assessment, which
included Rutherford classiﬁcation, ABI, and WIQ. As pre-
speciﬁed, patency was not evaluated beyond 1 year in the
Figure 1 Patient Flow Diagram
Enrollment by original random assignments, deaths (all-cause), withdrawals, and lost to follow-up through 2 years are shown. BMS ¼ bare-metal stent(s); DES ¼ drug-eluting
stent(s); PTA ¼ percutaneous transluminal angioplasty.
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2419single-arm study. However, the randomized trial speciﬁed
that all patients in the primary DES group, the provisional
stent groups (both DES and BMS), and a subgroup of PTA
patients (long-term PTA subgroup) undergo duplex ultra-
sound annually through 5 years to evaluate patency. Patients
were assigned to this long-term PTA subgroup using
adaptive random selection, with a goal of obtaining ultra-
sound follow-up beyond 1 year for approximately 50 patients
with successful PTA. According to the protocol, patients
who experienced PTA failure acutely (intraprocedurally) or
within 1 year were removed from the long-term PTA
subgroup, and their spots were ﬁlled by the subsequently
enrolled PTA patients. Additionally, as PTA failures accu-
mulated before reaching the approximately 50 patient goal,
the adaptive random selection increased the likelihood
of assignment of PTA patients to the long-term PTA
subgroup. PTA patients not assigned to the long-term PTA
subgroup were censored at 13.5 months. This resulted in
a subgroup of 42 patients (45 lesions) with successful PTA
who were eligible for duplex ultrasound follow-up beyond
1 year. This subgroup represents 58% of the PTA patients
who maintained patency through 1 year. Additionally, as
previously reported (12,13), stent integrity was assessed
using radiographs taken at 1-year follow-up, with the next
evaluations at 3 and 5 years in the randomized trial.
Deﬁnitions. Major adverse events included death, ampu-
tation, clinically driven target lesion revascularization
(TLR), target limb ischemia requiring surgical intervention,
and surgical vessel repair. Clinically driven TLR was deﬁnedas reintervention performed for 50% diameter stenosis
within 5 mm of the target lesion after documentation of
recurrent clinical symptoms. Event-free survival (EFS) was
deﬁned as freedom from adjudicated major adverse events
and freedom from worsening of the Rutherford classiﬁcation
by 2 classes or to class 5 or 6. At 2 years, primary patency
was evaluated in the randomized trial and deﬁned as <50%
stenosis from duplex ultrasonography (peak systolic velocity
ratio <2.0) or from arteriography when available (3). All
ultrasound examinations in the randomized trial were
independently reviewed by a core laboratory (VasCore, the
Vascular Ultrasound Core Laboratory, Massachusetts
General Hospital, Boston, Massachusetts). Clinical beneﬁt
was deﬁned as freedom from persistent or worsening
claudication, rest pain, ulcer, or tissue loss.
Statistical analysis. Outcomes through 2-year follow-up
have been assessed for available patients from both the
randomized trial and the single-arm study. Analyses were
performed using SAS version 9.3 (SAS Institute Inc., Cary,
North Carolina). The number of observations represents
patients, treated lesions, treated limbs, or implanted stents
as speciﬁed. Continuous variables are summarized with
mean  SD, with p values calculated using standard t tests.
Dichotomous and polytomous variables are reported as
counts and percentages, with p values calculated using Fisher
exact tests. Kaplan-Meier analyses were performed to assess
EFS, freedom from TLR, clinical beneﬁt, and patency over
time, with p values calculated using the log-rank test and
adjusted for multiplicity. The generalized estimating
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2420equation model was used to assess the inﬂuence of covariates
on patency and freedom from TLR.
Results
Of the 1,261 patients enrolled in the complementary studies,
908 were eligible for 2-year follow-up, with data available for
781 patients. Demographics, comorbidities, and lesion
characteristics are shown in Table 1. The mean lesion length
was approximately 65  40 mm in the randomized trial and
99.5  82.1 mm in the single-arm study.Table 1 Patient and Lesion Characteristics (12,13
Characteristic PTA Grou
Patient characteristics
Patients 238
Mean age (yrs) 67.7  10
Men 152 (63.9
Body mass index (kg/m2) 28.2  5
Claudication (Rutherford class 2 or 3) 90.7%
Critical limb ischemia (Rutherford classes 4–6) 8.5%
Diabetes 100 (42.0
Type 1 13 (13.0
Type 2 87 (87.0
Hypertension 194 (81.5
Hypercholesterolemia 166 (69.7
History of smoking 200 (84.0
Renal disease 25 (10.5
Pulmonary disease 38 (16.0
History of myocardial infarction 41 (17.2
Lesion characteristics
Lesions 251
Lesion location
SFA 232 (92.4
SFA/popliteal 6 (2.4%
Popliteal 13 (5.2%
Previous intervention to study lesion 14 (5.6%
Vascular access
Contralateral 189 (86.7
Ipsilateral 29 (13.3
Occlusiony 68 (27.4
Lesion length,z normal-to-normal (mm) 63.2  40
Lesion length,yz >20% stenosis (mm) 53.2  40
MLD in lesiony (mm) 1.1  0.
Percent diameter stenosisy (%) 78.4  17
In-stent restenosis NA
Ulcerationsy 47 (19.0
Lesion calciﬁcationy
None 12 (4.8%
Little 95 (38.2
Moderate 55 (22.1
Severe 87 (34.9
Values are n (%) or mean  SD. *Statistically signiﬁcant difference between
laboratory data for randomized trial and site data for single-arm study. zp val
signiﬁcantly more calciﬁcation than the PTA group.
DES ¼ drug-eluting stent(s); MLD ¼minimal luminal diameter; NA ¼ not app
femoral artery.Safety. In the randomized trial, the EFS rate through
2 years for the primary DES group was signiﬁcantly superior
to that for the PTA control group (86.6% vs. 77.9%, log-
rank p ¼ 0.02) (Fig. 2). As pre-speciﬁed, the overall PTA
control group included patients with optimal PTA, with
provisional BMS placement after acute PTA failure, and
with provisional DES placement after acute PTA failure.
These 3 cohorts comprised approximately 50%, 25%, and
25% of the overall PTA control group, respectively. The
2-year EFS rate for primary DES placement in the single-
arm study was 79.3%. The most common adverse event in)
Randomized Trial Single-Arm Study
p DES Group p Value DES
236 d 787
.6 67.9  9.6 0.88 67.1  9.5
%) 155 (65.7%) 0.70 578 (73.4%)
.6 28.4  5.3 0.71 27.4  4.3
90.5% >0.99 88.6%
8.7% 11.0%
%) 117 (49.6%) 0.11 285 (36.2%)
%) 19 (16.2%) 0.56 29 (10.2%)
%) 98 (83.8%) 256 (89.8%)
%) 210 (89.0%) 0.02* 627 (79.7%)
%) 180 (76.3%) 0.12 458 (58.2%)
%) 204 (86.4%) 0.70 632 (80.3%)
%) 24 (10.2%) >0.99 89 (11.3%)
%) 45 (19.1%) 0.39 71 (9.0%)
%) 50 (21.2%) 0.29 123 (15.6%)
247 d 900
%) 229 (92.7%) 0.63 857 (95.2%)
) 9 (3.6%) NA
) 9 (3.6%) 43 (4.8%)
) 13 (5.3%) 0.68 219 (24.3%)
%) 211 (85.4%) 0.78 NA
%) 36 (14.6%) NA
%) 79 (32.8%) 0.20 345 (38.3%)
.5 66.4  38.9 0.31 99.5  82.1
.3 54.6  40.7 0.50 NA
9 1.0  0.9 0.38 0.8  0.9
.1 79.8  17.0 0.38 84.6  16.4
NA d 119 (13.2%)
%) 40 (16.7%) 0.55 NA
) 4 (1.7%) <0.01*x 176 (19.6%)
%) 62 (25.7%) 294 (32.7%)
%) 85 (35.3%) 261 (29.0%)
%) 90 (37.3%) 168 (18.7%)
the PTA and DES groups in the randomized trial. yArteriographic core
ues were determined using Wilcoxon tests. xOverall, the DES group had
licable; PTA ¼ percutaneous transluminal angioplasty; SFA ¼ superﬁcial
Figure 2 2-Year Primary Safety Outcomes
The black curve shows 77.9% event-free survival (EFS) rate for the percutaneous transluminal angioplasty (PTA) group, and the red curve shows the signiﬁcantly higher
(p ¼ 0.02) 86.6% EFS rate for the primary drug-eluting stent (DES) group. The life table is included.
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2421both studies was clinically driven TLR. On the basis of
Kaplan-Meier estimates, the 2-year freedom from TLR rate
with primary DES placement was 86.6% in the randomized
trial and 80.5% in the single-arm study (Fig. 3).
There were no device-related deaths in either study. In
the randomized trial, all-cause death (e.g., malignancy,
pulmonary disease, congestive heart failure) included
8 patients (3.4%) in the PTA group and 18 patients (7.6%)
in the primary DES group through 2 years. In the single-
arm study, all-cause death through 2 years included 41
patients (5.2%). There was no signiﬁcant difference in the
all-cause death rates among these 3 groups (p ¼ 0.12).
Amputation (<1%) and worsening of Rutherford classiﬁ-
cation (<2%) were rare in both studies through 2 years.
There were no reports of adverse drug effects related to the
paclitaxel coating.
Patency. In the primary analysis for the randomized trial,
the 2-year primary patency rate of 74.8% for the primary
DES group was signiﬁcantly superior (log-rank p < 0.01;
Fig. 4) to the 26.5% for the long-term PTA subgroup. As
pre-speciﬁed for the primary analysis, acute PTA failure was
counted as a loss of patency. Primary DES treatment was
also signiﬁcantly superior (p < 0.01) to PTA for several
patient and lesion subgroups analyzed (Fig. 5).
In secondary analyses (Fig. 4), the 2-year primary patency
rate for the primary DES group was: 1) signiﬁcantly superior(log-rank p < 0.01) to the 53.4% rate for the optimal PTA
group (a group that excluded patients who experienced acute
PTA failure); 2) signiﬁcantly superior (log-rank p < 0.01) to
the 57.3% rate for the patients with optimal PTA and
provisional BMS placement after acute PTA failure; and 3)
signiﬁcantly superior (log-rank p ¼ 0.01) to the 64.3% rate
for the overall PTA control group that consisted of patients
with optimal PTA (50%) and with provisional BMS (25%)
or provisional DES (25%) placement after acute PTA
failure. Additionally, of PTA lesions that were still patent at
1 year, 13.7% (10 of 73) lost patency between 12 and
24 months, compared with 9.3% (17 of 182) of primary
DES lesions (p ¼ 0.37) (Fig. 6).
Finally, in the randomized trial, evaluation of the provi-
sional stent groups, which provides a direct assessment of
the paclitaxel effect, showed a superior 2-year primary
patency rate of 83.4% for provisional DES compared with
64.1% for provisional BMS (log-rank p < 0.01) (Fig. 7).
Through 2 years, there was no signiﬁcant difference in
patency for primary DES compared with provisional DES
placement (log-rank p ¼ 0.11). Of BMS lesions that were
still patent at 1 year, 12.2% (5 of 41) lost patency between
12 and 24 months, compared with 7.4% (4 of 54) of
provisional DES lesions (p ¼ 0.49) (Fig. 6).
Covariates. An analysis of covariates for TLR and patency
was performed, which included all DES patients from the
Figure 3 2-Year Freedom From TLR Outcomes for Primary DES Patients
The red curve shows 86.6% freedom from target lesion revascularization (TLR) in the randomized trial, and the black curve shows 80.5% freedom from TLR in the single-arm
study. The life table is included. DES ¼ drug-eluting stent(s).
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2422randomized trial (Table 2). Smoking was the only signiﬁcant
factor in the TLR analysis, with the TLR rate signiﬁcantly
reduced for DES patients who had never smoked compared
with those still smoking. Duration of dual-antiplatelet
therapy was the only signiﬁcant factor in the patency anal-
ysis. There was a higher patency rate for DES patients on
dual-antiplatelet therapy at 1 month compared with those
not on dual-antiplatelet therapy. However, there was no
evidence of a higher patency rate for DES patients on dual-
antiplatelet therapy at both 1 and 3 months compared with
1 month only.
Clinical beneﬁt. The Rutherford classiﬁcation, ABI, and
WIQ score each signiﬁcantly improved (p  0.01) from pre-
procedure to 2 years in both the primary DES and PTA
groups in the randomized trial, with no signiﬁcant differ-
ences between the groups. In the single-arm study, these
scores also signiﬁcantly improved (p < 0.01) from pre-
treatment to 2 years.
On the basis of Kaplan-Meier estimates in the random-
ized trial, the post-treatment clinical beneﬁt index was
sustained through 2 years in 81.8% of the primary DES
group compared with 71.3% of the overall PTA control
group (log-rank p < 0.01) (Fig. 8). Patients in the provi-
sional DES group also sustained greater clinical beneﬁt
through 2 years compared with the provisional BMS group
(83.9% vs. 68.4%) (Fig. 9).Discussion
The previously published 1-year results of the Zilver PTX
Randomized Clinical Trial document the beneﬁts of
a paclitaxel-coated DES over BMS-assisted PTA for the
treatment of patients with femoropopliteal disease, including
improved freedom from TLR and vessel patency (12). This
included a direct comparison of provisional DES with BMS
placement after failed primary PTA, which showed signiﬁ-
cantly greater 1-year patency with the DES. This beneﬁt at
1 year amounted to a 50% reduction in restenosis with the
DES relative to the BMS. These statistically signiﬁcant
differences are bolstered by the 1-year outcomes published
for the complementary Zilver PTX Single-Arm Study,
which evaluated patients with more complex lesions and
detailed similar TLR and patency rates for the DES to those
reported from the randomized trial (13).
Ever since initial clinical trials for the treatment of
patients with coronary artery disease showed superior
effectiveness of DES compared with BMS at 6 to
12 months, there have been questions concerning the
sustainability of these beneﬁts in certain groups. Now, long-
term follow-up after coronary interventions conﬁrms the
durability of the initial results for DES compared with
BMS, especially for patients with diabetes and for smaller
coronary arteries (15–17).
Figure 5
Patency Odds Ratio for DES Compared With BMS
Among Subgroups of Interest
The diamonds indicate the point estimates, and the lines indicate the 95%
conﬁdence intervals (CIs). BMS ¼ bare-metal stent(s); DES ¼ drug-eluting stent(s).
Figure 4 2-Year Primary Effectiveness Outcomes
The black curve shows the 26.5% primary patency rate for the percutaneous transluminal angioplasty (PTA) group (as pre-speciﬁed, acute PTA failure was a loss of patency), and
the red curve shows the signiﬁcantly higher (p < 0.01) 74.8% primary patency rate for the drug-eluting stent (DES) group. The life table is included. Secondary evaluations also
show that the primary patency rate for the DES (red curve) is 1) signiﬁcantly higher (p < 0.01) than the 53.4% rate for optimal PTA (dashed gray curve), a group that excluded
patients who experienced acute PTA failure; 2) signiﬁcantly higher (p < 0.01) than the 57.3% rate for optimal PTA with provisional bare-metal stent (BMS) placement (solid blue
curve); and 3) signiﬁcantly higher (p¼ 0.01) than the 64.3% rate for the overall PTA control group (solid gray curve), which consisted of patients with optimal PTA (50%) and with
provisional BMS (25%) or provisional DES (25%) placement after acute PTA failure.
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2423Long-term beneﬁts after DES placement in the femo-
ropopliteal arteries have not been demonstrated previously.
Two-year patency results from the randomized trial and
TLR rates from both the randomized and single-arm studies
reinforce the 1-year DES outcomes previously published for
both Zilver PTX studies (12,13). The 2-year freedom from
TLR rate for single-arm study patients is similar to that in
the randomized trial, considering the more challenging
lesions (e.g., longer, in-stent restenosis) enrolled.
The 2-year freedom from TLR for primary DES
implantation in the randomized trial of 86.6% compares
favorably with recently published BMS trials. The 2-year
freedom from TLR in the RESILIENT (Randomized
Study Comparing the Self-Expanding LifeStent vs.
Angioplasty Alone in Lesions Involving the SFA and/or
Proximal Popliteal Artery) trial, which enrolled femo-
ropopliteal lesions of lengths comparable to those in the
Zilver PTX randomized trial, was 77.8% (18). Similarly, the
2-year patency of 74.8% for the primary DES group in the
randomized trial compares favorably with published BMS
outcomes, including the 2-year patency rate of 54.3% for the
BMS studied in longer femoropopliteal lesions in the
Figure 6
Percentage of Lesions With Loss of Patency Between
12 and 24 Months
Of lesions that were still patent at 1 year, 13.7% in the percutaneous transluminal
angioplasty (PTA) group (black bar) and 9.3% of the primary drug-eluting stent
(DES) lesions (red bar) lost patency between 12 and 24 months. Of provisionally
stented lesions that were still patent at 1 year, 12.2% treated with provisional
bare-metal stents (BMS) (black hashed bar) and 7.4% treated with provisional
DES (red hashed bar) lost patency between 12 and 24 months.
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2424ABSOLUTE (Balloon Angioplasty Versus Stenting With
Nitinol Stents in the Superﬁcial Femoral Artery) trial (19).
The Zilver PTX randomized trial showed signiﬁcantly
greater 2-year patency in the primary DES group compared
with the long-termPTAsubgroup (74.8%vs. 26.5%,p< 0.01).Figure 7 Secondary 2-Year Evaluation Comparing the Effectiveness o
The black curve shows the 64.1% primary patency rate for lesions undergoing provisiona
angioplasty (PTA) failure, and the red curve shows the signiﬁcantly higher (p < 0.01) 83
placement after acute PTA failure. The life table is included.The results showed no evidence of late convergence between
these groups, as the loss of patency between 1 and 2 years was
9.3% with primary DES and 13.7% with PTA.
The randomized trial also demonstrated signiﬁcantly
greater 2-year patency in the provisional DES group
compared with the provisional BMS group (83.4% vs.
64.1%, p < 0.01). Again, there was no evidence of late
convergence between these groups, as the loss of patency
between 1 and 2 years was 7.4% for provisional DES and
12.2% for provisional BMS. The loss of patency between
1 and 2 years in the provisional BMS group is also similar to
the reduction in patency over an identical period in pub-
lished BMS trials for SFA disease, including a 13.8% loss of
patency during year 2 in the ABSOLUTE trial (19). In the
same trial, the loss of patency during year 2 for the PTA arm
was 15.8% (19).
A covariate analysis for patients receiving the DES in the
randomized trial included many of the factors generally
considered to have potential impact on TLR and patency,
such as reference vessel diameter, lesion length, calciﬁcation,
total occlusion, and diabetes. Only smoking signiﬁcantly
affected TLR, and only dual-antiplatelet therapy signiﬁ-
cantly affected patency. Speciﬁcally, DES patients adhering
to dual-antiplatelet therapy at 1 month had a higher patency
rate than those on single-antiplatelet therapy. A signiﬁcant
added beneﬁt, however, could not be demonstrated for DESf Provisional BMS and Provisional DES
l bare-metal stent (BMS) placement following acute percutaneous transluminal
.4% primary patency rate for lesions undergoing provisional drug-eluting stent (DES)
Table 2 Covariate Analysis
2-Year Covariate
TLR
p Value
Patency
p Value
Diabetes 0.63 0.16
Smoking status 0.02* 0.19
Rutherford classiﬁcation 0.81 0.87
Number of patent runoff vessels 0.59 0.44
De novo/restenotic lesions 0.07 0.81
Pre-dilation 0.53 0.26
Percent diameter stenosis 0.92 0.57
Total occlusion 0.09 0.66
Reference vessel diameter 0.55 0.07
Calciﬁcation 0.22 0.35
Lesion length 0.75 0.60
Lesion location 0.56 0.45
Acute PTA failure 0.45 0.36
Dual-antiplatelet therapy 0.55 0.03y
*Statistically signiﬁcant. Odds ratio of 0.29 (95% conﬁdence interval: 0.07 to 1.13) for never
smoked versus still smoking. yStatistically signiﬁcant. Odds ratio of 0.36 (95% conﬁdence interval:
0.11 to 1.17) for no antiplatelet therapy versus antiplatelet therapy only at 1 month.
PTA ¼ percutaneous transluminal angioplasty; TLR ¼ target lesion revascularization.
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2425patients on dual-antiplatelet therapy over a longer interval of
3 months. This ﬁnding is not conclusive, but weighing the
positive and negative consequences when determining the
duration of dual-antiplatelet therapy in patients receivingFigure 8 2-Year Post-Treatment Clinical Beneﬁt Index Results for Pr
The clinical beneﬁt index was deﬁned as freedom from persistent or worsening claudicat
shows that 71.3% of patients in the percutaneous transluminal angioplasty (PTA) group m
primary drug-eluting stent (DES) group maintained clinical beneﬁt (p < 0.01). The life tabDES, as well as BMS, in the SFA is important to further
consider. Also, the optimal administration of antiplatelet
therapy with peripheral DES should not be assumed iden-
tical to the coronary artery DES experience.
In terms of potential adverse drug effects related to the
paclitaxel coating on the DES, published 1-year results from
the randomized and single-arm studies did not report any
untoward events (12,13). Similarly, no adverse effects or
reactions associated with the paclitaxel coating were
observed through 2 years in either study.
Study limitations. A limitation of the randomized trial is
the inability to make a comprehensive comparison of the
primary therapies at 2 years using all of the patients initially
randomized to the PTA control group. Before initiating
enrollment, there was agreement among investigators that
follow-up of all patients in the PTA group beyond the
1-year primary endpoint was unnecessary and impractical.
Consequently, it was determined to provide follow-up
beyond 1 year for all patients receiving stents (primary
DES, provisional DES, and provisional BMS) and a
subgroup of control patients who experienced successful
initial PTA and maintained patency through 1 year (long-
term PTA subgroup). These patients were selected by a
pre-speciﬁed process of adaptive random selection, which
allowed a long-term (2-year) comparison between DES andimary DES Compared With PTA Treatment
ion, rest pain, ulcer, or tissue loss after the initial study treatment. The black curve
aintained clinical beneﬁt, and the red curve shows that 81.8% of patients in the
le is included.
Figure 9 2-Year Post-Treatment Clinical Beneﬁt Index Results for Provisional DES Compared With Provisional BMS Treatment
The black curve shows that 68.4% of patients undergoing provisional bare-metal stent (BMS) placement after acute percutaneous transluminal angioplasty (PTA) failure
maintained clinical beneﬁt, and the red curve shows that 83.9% of patients undergoing provisional drug-eluting stent (DES) placement after acute PTA failure maintained clinical
beneﬁt. The life table is included.
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2426PTA by following 42 optimal PTA patients who maintained
patency through the 1-year primary endpoint. The PTA
patients who maintained patency through 1 year and were
not randomized to the long-term PTA subgroup were
censored at 13.5 months, the pre-speciﬁed end of the 1-year
follow-up window. Accordingly, a limitation of the study is
the potential for bias introduced by the selection of the long-
term PTA subgroup. However, through 1 year, the patency
rate for the long-term PTA subgroup was not signiﬁcantly
different from the rest of the optimal PTA group (log-rank
p ¼ 0.08).
There was similar improvement (p  0.01) in Ruth-
erford classiﬁcation, ABI, and WIQ score from pre-
procedure to 2 years in both the primary DES and PTA
groups in the randomized trial. However, these clinical
outcomes include patients who had TLR, and more
frequent TLR was required in the PTA group than the
DES group to achieve these similar clinical outcomes. The
protocol also did not include treadmill exercise testing.
However, the evaluation of the post-treatment clinical
beneﬁt index (deﬁned as freedom from persistent or
worsening claudication, rest pain, ulcer, or tissue loss)
allowed a secondary clinically based evaluation of patient
beneﬁt through 2 years. These results favored the DES over
the PTA control group and also favored provisional DES
over provisional BMS.Finally, although the randomized trial results demonstrate
sustained superior EFS and patency through 2 years for
primary DES compared with PTA and for provisional
DES compared with provisional BMS, the study lacked a
primary BMS group and therefore did not directly compare
primary DES with primary BMS. It is also important to
recognize the limitation of broadening the implications to
femoropopliteal lesions longer than 14 cm, which were
excluded from the randomized trial. However, the 2-year
outcomes from the complementary single-arm study,
which included lesions up to 40 cm long (with a mean
length of approximately 10 cm and approximately one-
quarter >15 cm), reinforce the patency results from the
randomized trial, with similar TLR rates at 1 and 2 years in
both studies.
Conclusions
The combination of 2-year outcomes from the comple-
mentary Zilver PTX studies, including safety, patency,
clinical beneﬁt, and the absence of adverse events related to
the paclitaxel drug coating, support the sustained safety and
effectiveness of the DES in patients with de novo or rest-
enotic femoropopliteal arterial lesions, the superiority of the
DES to PTA, and the long-term beneﬁt of the drug coating
over the corresponding BMS.
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